This content is only available within our institutional offering.
09 Sep 2019
AstraZeneca’s Anifrolumab successfully navigates the complexity of a Phase III lupus clinical trial, will Lupuzor be next?
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
AstraZeneca’s Anifrolumab successfully navigates the complexity of a Phase III lupus clinical trial, will Lupuzor be next?
ImmuPharma plc (IMM:LON) | 2.1 0 1.4% | Mkt Cap: 8.93m
- Published:
09 Sep 2019 -
Author:
Dr. Navid Malik -
Pages:
7
LupuzorTM owned and developed by ImmuPharma is a valuable late-stage asset and is potentially a key peptide therapeutic drug in the fight against Lupus. Last year, the drug completed the first of two-Phase III clinical trials; we commented on the data and analysis of the trial result, in extensive detail in our initiation report dated: 28 May 2019. The second LupuzorTM Phase III clinical trial, could begin after the agreement of the trial design with regulators (possibly based on a targeted group encompassing Lupus patients that are anti-dsDNA auto-antibody positive) and once a licensing partner or funding route is identified. In this note, we comment on and evaluate the results of AstraZeneca’s recently disclosed Phase III Lupus trial, (Tulip II), which we believe will potentially have a positive impact on the Lupus field and the prospects for partnering LupuzorTM, as well as its path
report. We reiterate our BUY rating on ImmuPharma plc and a Target Price of 76p.